| Popis: |
Shadi Zari Department of Dermatology, College of Medicine, University of Jeddah, Jeddah, Saudi ArabiaCorrespondence: Shadi Zari, Department of Dermatology, College of Medicine, University of Jeddah, Jeddah, Saudi Arabia, Email shadizarimd@gmail.comObjectives: To assess the effectiveness of adipocyte-derived mesenchymal stem cells-conditioned media (ADSC-CM) formulation in telogen effluvium patients.Methods: A retrospective cohort study was conducted at a dermatology clinic in Jeddah, Saudi Arabia. The study included 50 consecutive patients aged 20– 70 years, who were diagnosed with telogen effluvium. All patients received five monthly sessions of the same commercial ADSC-CM formulation, using a standardized application protocol. Pre- and post-intervention changes in trichometry parameters were analyzed.Results: There was a significant increase in mean hair density (up to 29.01 hair/cm2; effect size 0.7– 1.0), cumulative hair thickness (up to 2.67 units; effect size 0.7– 1.4), and the number of follicular hair units (up to 19.96%; effect size 1.0– 1.3) in all scalp regions (p < 0.001), associated with a decrease in mean trichometry-derived Sinclair scale by 0.8– 1.3 (p < 0.001). Positive outcomes were observed in 70%– 92% of the patients depending on the parameter and scalp region. There was no impact of the patient’s age on ADSC-CM efficacy.Conclusion: ADSC-CM was successfully applied as a new treatment option for patients with telogen effluvium. These findings provide another therapeutic and research area for dermatologists to optimize the management of telogen effluvium and reduce its impact on patients.Plain Language Summary: Hair loss can be a distressing experience. Telogen effluvium, a common type of hair loss, was the focus of a study in Saudi Arabia. The goal? To see if a new treatment using a mixture of cytokines, growth factors, and proteins from fat cell-derived stem cells (known as ADSC-CM) could help.The researchers worked with 50 people aged between 20 and 70, all of whom were experiencing telogen effluvium. The treatment involved five monthly sessions of the ADSC-CM product. The team measured aspects of hair growth before and after the treatment.What did they find? Encouraging signs! Hair density and thickness significantly improved across the scalp. Additionally, the severity of the hair loss condition was reduced. Between 70% and 92% of people saw positive changes depending on the area of the scalp and the specific measurement.The exciting part is that the age of the person did not affect how well the treatment worked. This suggests it could benefit a wide range of people.In a nutshell, this study suggests ADSC-CM may be a new and effective way to help people experiencing telogen effluvium. More research is needed, but it is a promising avenue for dermatologists to explore and could potentially help reduce the impact of hair loss on people’s lives.Keywords: hair loss, alopecia, stem cells, stem-cell conditioned media, hair regeneration |
